WO2007011955A3 - Drug-containing implants and methods of use thereof - Google Patents

Drug-containing implants and methods of use thereof Download PDF

Info

Publication number
WO2007011955A3
WO2007011955A3 PCT/US2006/027894 US2006027894W WO2007011955A3 WO 2007011955 A3 WO2007011955 A3 WO 2007011955A3 US 2006027894 W US2006027894 W US 2006027894W WO 2007011955 A3 WO2007011955 A3 WO 2007011955A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
present
methods
implants
containing implants
Prior art date
Application number
PCT/US2006/027894
Other languages
French (fr)
Other versions
WO2007011955A2 (en
Inventor
Steven Siegel
Karen Winey
Original Assignee
Univ Pennsylvania
Steven Siegel
Karen Winey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/183,232 external-priority patent/US8221778B2/en
Priority claimed from US11/195,845 external-priority patent/US8329203B2/en
Priority to JP2008522903A priority Critical patent/JP5405825B2/en
Priority to AU2006269927A priority patent/AU2006269927B2/en
Priority to MX2008000573A priority patent/MX2008000573A/en
Priority to CA2614601A priority patent/CA2614601C/en
Priority to MX2014012310A priority patent/MX362908B/en
Priority to US11/988,137 priority patent/US8741327B2/en
Application filed by Univ Pennsylvania, Steven Siegel, Karen Winey filed Critical Univ Pennsylvania
Priority to KR1020087003822A priority patent/KR101283946B1/en
Priority to EP06787745A priority patent/EP1909689A4/en
Publication of WO2007011955A2 publication Critical patent/WO2007011955A2/en
Publication of WO2007011955A3 publication Critical patent/WO2007011955A3/en
Priority to US13/490,787 priority patent/US8802127B2/en
Priority to US14/286,168 priority patent/US9439905B2/en
Priority to US14/540,828 priority patent/US9717799B2/en
Priority to US15/627,349 priority patent/US9925268B2/en
Priority to US15/627,389 priority patent/US9895447B2/en
Priority to US15/863,483 priority patent/US10111960B2/en
Priority to US16/174,083 priority patent/US10736965B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222—Steroids, e.g. corticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Abstract

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
PCT/US2006/027894 2004-01-12 2006-07-18 Drug-containing implants and methods of use thereof WO2007011955A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP06787745A EP1909689A4 (en) 2005-07-18 2006-07-18 Drug-containing implants and methods of use thereof
KR1020087003822A KR101283946B1 (en) 2005-07-18 2006-07-18 Drug-containing implants and methods of use thereof
AU2006269927A AU2006269927B2 (en) 2004-01-12 2006-07-18 Drug-containing implants and methods of use thereof
MX2008000573A MX2008000573A (en) 2005-07-18 2006-07-18 Drug-containing implants and methods of use thereof.
CA2614601A CA2614601C (en) 2005-07-18 2006-07-18 Drug-containing implants and methods of use thereof
JP2008522903A JP5405825B2 (en) 2005-07-18 2006-07-18 Drug-containing implant and method of using the same
MX2014012310A MX362908B (en) 2005-07-18 2006-07-18 Drug-containing implants and methods of use thereof.
US11/988,137 US8741327B2 (en) 2004-01-12 2006-07-18 Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
US13/490,787 US8802127B2 (en) 2004-01-12 2012-06-07 Risperidone-containing PLA:PGA implants and methods of use thereof
US14/286,168 US9439905B2 (en) 2004-01-12 2014-05-23 Risperidone-containing implants and methods of use thereof
US14/540,828 US9717799B2 (en) 2004-01-12 2014-11-13 Drug-containing implants and methods of use thereof
US15/627,389 US9895447B2 (en) 2004-01-12 2017-06-19 Drug-containing PLA implants and methods of use thereof
US15/627,349 US9925268B2 (en) 2004-01-12 2017-06-19 Drug-containing implants and methods of use thereof
US15/863,483 US10111960B2 (en) 2004-01-12 2018-01-05 9-OH-risperidone controlled release composition
US16/174,083 US10736965B2 (en) 2004-01-12 2018-10-29 Risperidone biodegradable implant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/183,232 2005-07-18
US11/183,232 US8221778B2 (en) 2005-01-12 2005-07-18 Drug-containing implants and methods of use thereof
US11/195,845 2005-08-03
US11/195,845 US8329203B2 (en) 2004-01-12 2005-08-03 Drug-containing implants and methods of use thereof

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US11/183,232 Continuation-In-Part US8221778B2 (en) 2004-01-12 2005-07-18 Drug-containing implants and methods of use thereof
US11/195,845 Continuation-In-Part US8329203B2 (en) 2004-01-12 2005-08-03 Drug-containing implants and methods of use thereof
US11/195,845 Continuation US8329203B2 (en) 2004-01-12 2005-08-03 Drug-containing implants and methods of use thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/988,137 A-371-Of-International US8741327B2 (en) 2004-01-12 2006-07-18 Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
US12/988,137 Continuation-In-Part US20110037616A1 (en) 2008-04-16 2009-03-12 Method for monitoring a traffic route for a means of transport of a predetermined kind
US13/490,787 Continuation US8802127B2 (en) 2004-01-12 2012-06-07 Risperidone-containing PLA:PGA implants and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2007011955A2 WO2007011955A2 (en) 2007-01-25
WO2007011955A3 true WO2007011955A3 (en) 2007-12-13

Family

ID=37669513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027894 WO2007011955A2 (en) 2004-01-12 2006-07-18 Drug-containing implants and methods of use thereof

Country Status (8)

Country Link
EP (1) EP1909689A4 (en)
JP (3) JP5405825B2 (en)
KR (1) KR101283946B1 (en)
CN (1) CN103637977A (en)
AU (1) AU2006269927B2 (en)
CA (1) CA2614601C (en)
MX (2) MX2008000573A (en)
WO (1) WO2007011955A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101283946B1 (en) * 2005-07-18 2013-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Drug-containing implants and methods of use thereof
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101801415B (en) 2007-05-25 2015-09-23 Rb医药品有限公司 The sustained delivery formulations of risperidone compounds
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
WO2010039722A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
JP6199539B2 (en) 2009-03-12 2017-09-20 デルポー，インコーポレイティド Implantable device for long-term delivery of drugs
JP2011001273A (en) * 2009-06-16 2011-01-06 Eci Inc WATER-SOLUBLE PREPARATION COMPRISING eMIP AS ACTIVE INGREDIENT
JP2013509448A (en) * 2009-11-02 2013-03-14 ニューパス インコーポレーテッド How to treat Parkinson's disease
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20130344125A1 (en) * 2010-11-26 2013-12-26 Thiresen Govender Drug delivery device
TWI552751B (en) * 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104922085B (en) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 A kind of risperidone implant and preparation method thereof
DK3377041T3 (en) 2015-11-16 2023-12-18 Medincell S A METHOD FOR FRAGMENTATION AND/OR TARGETING OF PHARMACEUTICALLY ACTIVE INGREDIENTS TO SYNOVIAL TISSUE
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US20020179096A1 (en) * 2000-10-20 2002-12-05 Siegel Steven J. Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216117A (en) * 1982-06-09 1983-12-15 Mitsui Toatsu Chem Inc Preparation of rod-shaped slow-releasing formed drug
JPS63203610A (en) * 1987-02-12 1988-08-23 ヘキスト・アクチエンゲゼルシヤフト Long life medicine comprising plural components for implant
JPS6471823A (en) * 1987-09-12 1989-03-16 Rohto Pharma Sustained remedy for vaginal candidiasis
JP2702729B2 (en) * 1988-02-24 1998-01-26 エーザイ株式会社 Sustained release implant
JPH04217914A (en) * 1990-05-10 1992-08-07 Nkk Corp Production of sustained release pharmaceutical
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
DE69327542T2 (en) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical ANTIPSYCHOTIC-CONTAINING MICROBALL FOR DELAYED RELEASE AND METHOD FOR THEIR PRODUCTION
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
EP1001743B1 (en) * 1997-06-04 2006-02-01 Debio Recherche Pharmaceutique S.A. Implants for controlled release of pharmaceutically active principles and method for making same
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
WO2003020200A2 (en) * 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2006516947A (en) * 2000-11-16 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド Novel pharmaceutical compound and method for producing and using the same
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
ITMI20031302A1 (en) * 2003-06-26 2004-12-27 Mediolanum Pharmaceuticals Ltd USE OF ETHANOL AS A PLASTICIZER TO PREPARE SUBCUTANEOUS IMPLANTS CONTAINING THERMALABLE ACTIVE PRINCIPLES DISPERSED IN A PLGA MATRIX.
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
ES2432556T3 (en) * 2004-08-04 2013-12-04 Evonik Corporation Methods for manufacturing supply devices and their devices
KR101283946B1 (en) * 2005-07-18 2013-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Drug-containing implants and methods of use thereof
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US20020179096A1 (en) * 2000-10-20 2002-12-05 Siegel Steven J. Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1909689A4 *

Also Published As

Publication number Publication date
EP1909689A4 (en) 2011-11-16
JP2009501798A (en) 2009-01-22
KR101283946B1 (en) 2013-07-15
JP6153952B2 (en) 2017-06-28
CN103637977A (en) 2014-03-19
AU2006269927A1 (en) 2007-01-25
EP1909689A2 (en) 2008-04-16
MX2008000573A (en) 2008-03-14
JP5405825B2 (en) 2014-02-05
CA2614601C (en) 2015-04-07
CA2614601A1 (en) 2007-01-25
JP2014001246A (en) 2014-01-09
KR20080033991A (en) 2008-04-17
AU2006269927B2 (en) 2013-05-16
WO2007011955A2 (en) 2007-01-25
MX362908B (en) 2019-02-21
JP2015078233A (en) 2015-04-23

Similar Documents

Publication Publication Date Title
WO2007011955A3 (en) Drug-containing implants and methods of use thereof
WO2007146426A3 (en) Nanoshells for drug delivery
WO2004010975A3 (en) Controlled drug delivery
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007023408A3 (en) 4d image-based planning methods and apparatus for targeted therapy
WO2007015739A3 (en) Pea-tempo/pea-bz coatings for controlled delivery of drugs from implantable medical devices
EP2407203A3 (en) Solid therapeutic agent for use in an implantable drug delivery device
WO2008036144A3 (en) Nanoshells on polymers
EP1781354A4 (en) An occludable intravascular catheter for drug delivery and method of using the same
WO2007126768A3 (en) Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
DE602005010788D1 (en) Pharmaceutical compositions for the safe administration of drugs used in the treatment of drug addiction
EP1809369A4 (en) Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto
AU2003245282A1 (en) Stent coatings with sustained drug release rate
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2010068281A3 (en) Contact lens drug delivery device
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
MX2007002189A (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery.
ATE554725T1 (en) SURGICAL ARTICLES FOR THE TREATMENT OF PELVIC DISEASES
ATE530142T1 (en) SURGICAL ARTICLES FOR THE TREATMENT OF PELVIC DISEASES
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
CY1120433T1 (en) MELATONIN AGRICULTURAL TREATMENT
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
WO2006085115A3 (en) Therapeutic uses of tomato extracts
HK1079993A1 (en) Drugs for treating vascular diseases
WO2008060618A3 (en) Use of genetic determinants in cardiovascular risk assessment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680034307.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006269927

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2614601

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/000573

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008522903

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006787745

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006269927

Country of ref document: AU

Date of ref document: 20060718

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087003822

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11988137

Country of ref document: US